3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
3
Brain Neoplasms
2
Uveal Melanoma
1
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Noonan Syndrome 6
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma, Large-Cell, Anaplastic
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
58
Nivolumab
37
aldesleukin
16
Cyclophosphamide
15
atezolizumab
12
Specimen Handling
11
Radiosurgery
10
Paclitaxel
10
Magnetic Resonance Spectroscopy
10
Ipilimumab
9
Interleukin-2
9
fludarabine
8
fludarabine phosphate
7
Docetaxel
7
Carboplatin
7
avelumab
6
Radiotherapy
6
durvalumab
5
Peripheral Blood Stem Cell Transplantation
5
Immune Checkpoint Inhibitors
5
Cisplatin
5
Bevacizumab
5
tislelizumab
4
temsirolimus
4
spartalizumab
4
Sirolimus
4
Pemetrexed
4
Oxaliplatin
4
Leucovorin
4
Cryosurgery
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
entrectinib
×
Dermatologic
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA